Literature DB >> 11876716

The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers.

A M P De Schryver1, G I Andriesse, M Samsom, A J P M Smout, H G Gooszen, L M A Akkermans.   

Abstract

BACKGROUND: Prucalopride is a selective and specific 5-hydroxytryptamine(4) receptor agonist that is known to increase stool frequency and to accelerate colonic transit. AIM: To investigate the effect of prucalopride on high-amplitude propagated contractions and segmental pressure waves in healthy volunteers.
METHODS: After 1 week of dosing (prucalopride or placebo in a double-blind, randomized, crossover fashion), colonic pressures were recorded in 10 healthy subjects using a solid-state pressure catheter with six sensors spaced 10 cm apart. Subjects kept diary records of their bowel habits (frequency, consistency and straining). High-amplitude propagated contractions were analysed visually, comparing their total numbers and using 10-min time windows. Segmental pressure waves were analysed using computer algorithms, quantifying the incidence, amplitude, duration and area under the curve of all detected peaks.
RESULTS: When taking prucalopride, stool frequency increased, consistency decreased and subjects strained less. Prucalopride just failed to increase the total number of high-amplitude propagated contractions (P=0.055). The number of 10-min time windows containing high-amplitude propagated contractions was increased by prucalopride (P=0.019). Prucalopride increased the area under the curve per 24 h (P=0.026).
CONCLUSIONS: The 5-hydroxytryptamine(4) receptor agonist prucalopride stimulates high-amplitude propagated contractions and increases segmental contractions, which is likely to be the underlying mechanism of its effect on bowel habits in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11876716     DOI: 10.1046/j.1365-2036.2002.01195.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  24 in total

Review 1.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

2.  Relamorelin to Treat Constipation: "Pusher" or Pushover?

Authors:  Gabrio Bassotti
Journal:  Dig Dis Sci       Date:  2016-03       Impact factor: 3.199

3.  Efficacy and Tolerability of Prucalopride in Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis.

Authors:  Sung-Wook Park; Seok-Pyo Shin; Ji Taek Hong
Journal:  Adv Ther       Date:  2020-04-22       Impact factor: 3.845

4.  Prucalopride: safety, efficacy and potential applications.

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

5.  Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial.

Authors:  Andres Acosta; Michael Camilleri; Irene Busciglio; Amy Boldingh; Alfred D Nelson; Duane Burton
Journal:  Dig Dis Sci       Date:  2015-10-14       Impact factor: 3.199

6.  Effect of enterokinetic prucalopride on intestinal motility in fast rats.

Authors:  Hui-Bin Qi; Jin-Yan Luo; Xin Liu
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

7.  Prucalopride: the evidence for its use in the treatment of chronic constipation.

Authors:  Georges Coremans
Journal:  Core Evid       Date:  2008-06

8.  Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.

Authors:  Cornelius E J Sloots; An Rykx; Marina Cools; Rene Kerstens; Martine De Pauw
Journal:  Dig Dis Sci       Date:  2010-04-30       Impact factor: 3.199

9.  The association between prucalopride efficacy and constipation type.

Authors:  A M Jadav; C M McMullin; J Smith; K Chapple; S R Brown
Journal:  Tech Coloproctol       Date:  2013-05-24       Impact factor: 3.781

Review 10.  Prucalopride: a review of its use in the management of chronic constipation.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.